IBB and XBI broke out.
Will EXEL follow the sector trend with an excellent clinical read outs across multiple oncology fields?
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
